Kenvue

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kenvue (KVUE) reports strong Q2 earnings, eyes China growth

Kenvue's Q2 performance showcased robust net sales, organic growth, and strategic investments in key segments. The company's focus on consumer trust, supply chain enhancements, and capital allocation strategy underpin its resilience. Challenges include managing inflationary pressures and sustaining growth post-COVID, but opportunities in China and ongoing investments position Kenvue for future success.

Kenvue (KVUE) reports solid Q3 performance amidst segment challenges

Kenvue (KVUE) delivered a solid Q3 performance, showcasing strength in key segments despite challenges in others.
The company's strategic initiatives, focus on innovation, and outlook for growth opportunities position it well for future success.
Efforts to address challenges in specific segments and capitalize on opportunities demonstrate a proactive approach to sustaining growth and profitability.
Overall positive outlook on third-quarter results reflects the company's strong model, portfolio, and cash flow generation capabilities.

Kenvue reports mixed 2023 performance, focuses on growth strategies

Kenvue's 2023 performance saw organic growth but faced challenges in specific segments, leading to adjustments for 2024. The company aims to drive growth through operational efficiencies, increased brand investments, and a focus on consumer engagement. Challenges in U.S. in-store execution prompted a recovery plan and leadership changes.

Kenvue surpasses Q1 expectations, eyes China growth amid challenges

Kenvue's Q1 performance exceeded expectations, driven by key segments and brands.
Strategic focus on cost optimization, operational efficiency, and brand impact.
Challenges include stabilizing declining segments and managing hyperinflation impact.
Opportunities lie in growing China business, operational reinvention, and new leadership.

Kenvue reports solid Q2 performance and optimistic outlook for 2024

Kenvue's Q2 performance reflects steady growth and improved profitability, driven by strategic initiatives and strong brand performance. While cost management and increased marketing spend pose challenges, the company's focus on brand investment and long-term value creation offers promising opportunities for future growth and shareholder returns.

Kenvue reports Q3 growth, tackles Skin Health challenges, eyes savings

Kenvue's Q3 performance showed organic growth and strong financial metrics.
While facing challenges in the Skin Health segment, the company is focusing on recovery.
Investments in marketing and efficiency improvements highlight growth opportunities.
Executives addressed key questions on guidance, inventory levels, and growth strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

Tylenol, Listerine and Band-Aid maker Kenvue has attracted the activist investor, according to a report.

Starboard Targets Another Health Company. Why Kenvue Is in Its Sights.

Activist investor Starboard Value has taken a sizeable stake in Kenvue, the maker of Tylenol and Listerine, and is seeking changes, according to reports Sunday night.

Starboard reportedly takes big stake in Tylenol maker Kenvue

Activist investor Starboard Value has a stake in Kenvue , which makes Listerine and Tylenol, two sources familiar with the matter told Reuters on Sunday.

Activist investor Starboard Value takes stake in consumer products maker Kenvue, sources say

Starboard wants Kenvue, which was spun out of Johnson & Johnson last year and has a market value of over $40 billion, to make changes to boost its share price.

Activist Starboard Value Takes Stake in Tylenol-Maker Kenvue

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) will announce its third quarter 2024 financial results before market open on November 7, 2024.

Kenvue to Announce Third Quarter 2024 Results on November 7, 2024

Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue's common stock.

Kenvue Declares Quarterly Cash Dividend

PepsiCo

Target

Target, PepsiCo, and Kenvue have high yields and inexpensive valuations.

All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year

Archer-Daniels-Midland Company

Black Hills

California Water Service Group

Con Ed

Fortis

Genuine Parts

Hormel Foods

Coca-Cola

Altria

Middlesex Water

National Fuel Gas

Northwest Natural Gas

PPG Industries

SJW Group

Stanley Black & Decker

Sysco

United Bankshares

Universal Corp

A Dividend King is a stock with 50 or more consecutive years of dividend increases per suredividend.com. The 53 Dividend Kings, screened as of October 8, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 13.99%-20.65% topped by Northwest Natural and United Bankshares. By yield, Altria tops all. Top-ten October dogs: HRL, KVUE, FRT, UBSI, FTS, BKH, NWN, CDUAF, UVV, and MO averaged 4.87% in yield.

Buy 7 October Dividend Kings, Watch 10 More

Amcor Plc

Franklin Resources

Chevron

Fastenal

Federal Realty Investment Trust

Johnson & Johnson

Medtronic

Realty Income Corp

J. M. Smucker

Solventum Corporation

T. Rowe Price Group

V.F.

Walgreens

"Dividend Aristocrats... in the S&P500 Index… have raised their annual payouts every year for at least 25 consecutive years." -- Kiplinger.com/Investing. 67 Aristocrats, screened as of October 7, 2024 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 10.5%-20.13% topped-by Franklin & Target.

Buy 4 October Dividend Aristocrats & Watch 10

Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Kenvue (KVUE) Beat Estimates Again in Its Next Earnings Report?

Just like trying to catch falling knives, chasing stocks can be a dangerous endeavor. In this update, I share my latest thoughts on Kenvue stock, focusing specifically on the Q2 2024 results that sent the stock soaring 25%. I've incorporated the latest results into my valuation model and explain what the market is currently pricing in for KVUE stock.

Kenvue: Turning Cautious On The Stock While Remaining Optimistic On The Business

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) is releasing its first Task Force on Climate-related Financial Disclosures (TCFD) report.

Kenvue Drives Climate Action Strategy Forward

Emerson Electric

Leggett & Platt

Stepan

"What is a Dividend King? A stock with 50 or more consecutive years of dividend increases.” - suredividend.com. The 53 Dividend Kings, screened as of Sept. 10, represented eight of 11 Morningstar Sectors. Broker-targeted top 10 net gains ranged around 11.59%-35.94%, topped by Emerson and Stephan. By yield, Altria tops all. Top 10 September dogs: HRL, KVUE, FRT, FTS, UBSI, BKH, NWN, CDUAF, UVV, and MO averaged 4.70% in yield.

Buy 7 September Dividend Kings, Watch 9 More

Air Products and Chemicals

Exxon Mobil

The S&P 500 Dividend Aristocrats list was rebalanced in January 2024, with notable changes including the removal of Walgreens and 3M, and the addition of Fastenal and Kenvue.

Buy 4 September Dividend Aristocrats And Watch 6

Kenvue Inc. KVUE — the parent company of well-known pharmacy items like Listerine, Mylanta, and Tylenol — is showing a bullish pattern on the charts Tuesday.

Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart

Anheuser-Busch InBev

24/7 Wall St. Insights Social Security is not enough to provide for a comfortable retirement.

5 Dividend Kings Provide Perfect Passive Income Streams for Retirement

Illinois Tool Works

Coca-Cola and Pepsi are two proven and reliable dividend stocks. Kenvue's high yield and established portfolio of consumer health brands make it a passive income powerhouse.

Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.

Arch Capital

Axon Enterprise

Clorox

CrowdStrike

Fortinet

Kellogg

Eli Lilly

Progressive

Starbucks

Kellanova led the list after accepting a takeout offer from Mars, while Starbucks might have been the month's biggest positive surprise.

Here are the S&P 500's best-performing stocks in August

The maker of Tylenol defeated a lawsuit by consumers who said they were deceived into overpaying for "Rapid Release" gelcaps that did not relieve pain faster than cheaper tablets, including those labeled Extra Strength and Regular Strength.

Tylenol maker defeats lawsuit over labeling

AbbVie

Abbott Labs

Cincinnati Financial

Trump Media & Technology Group Corp

Lancaster Colony

Lowe's

Procter & Gamble

Parker-Hannifin

Walmart

The former president's recent regulatory filing disclosed positions in 21 Dividend Kings. Most of these stocks underperformed the S&P 500 over the last five years.

Donald Trump Owns These 21 Dividend Kings. Should You?

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced the Company's participation in the Barclays Global Consumer Staples Conference in Boston, Massachusetts. Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will participate in a fireside chat on Thursday, September 5, 2024, at 3:00 p.m. Eastern Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be.

Kenvue Announces Participation in the Barclays Global Consumer Staples Conference

Dividends represent the portion of a company's earnings paid to shareholders, typically on a quarterly basis.

Passive Income Matters: These 3 Stocks Are Perennial Dividend Growers Worth Buying

Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future.

Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon

New Product Line Features Two Moisturizers Designed to Defend and Support the Skin's Natural Collagen SKILLMAN, N.J. , Aug. 15, 2024 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) ("Kenvue" or the "Company"), the world's largest pure-play consumer health company by revenue, is launching Neutrogena®1 Collagen Bank™ featuring the Company's patented micro-peptide technology.

Kenvue Introduces Patented Micro-Peptide Technology with Neutrogena® Collagen Bank™ Launch

News for Kenvue Stock (KVUE)